ProMetic Life Sciences Inc. (TSE:PLI) insider Jonathan Booth bought 75,000 shares of the stock in a transaction dated Friday, October 6th. The stock was bought at an average cost of C$1.21 per share, with a total value of C$90,750.00.

ProMetic Life Sciences Inc. (TSE PLI) traded up 1.32% on Wednesday, reaching $1.54. The company’s stock had a trading volume of 340,866 shares. The firm has a 50-day moving average of $1.47 and a 200-day moving average of $1.77. The company’s market capitalization is $1.09 billion. ProMetic Life Sciences Inc. has a one year low of $1.12 and a one year high of $3.24.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/11/insider-buying-prometic-life-sciences-inc-pli-insider-purchases-75000-shares-of-stock.html.

A number of equities research analysts have recently weighed in on PLI shares. Canaccord Genuity lowered their target price on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating for the company in a research note on Monday, June 19th. Scotiabank lowered their price target on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating for the company in a research report on Friday, July 7th. TD Securities lowered their price target on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a research report on Wednesday, August 16th. Royal Bank Of Canada lowered their price target on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a research report on Wednesday, August 16th. Finally, National Bank Financial upped their price target on ProMetic Life Sciences from C$2.00 to C$2.50 in a research report on Wednesday, August 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of C$3.60.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Insider Buying and Selling by Quarter for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.